Does long-term use of ticagrelor reduce the risk of cardiovascular death, myocardial infarction, or stroke in patients with a myocardial infarction more than 1 year previously?
Long-term use of ticagrelor in patients with a prior myocardial infarction (>1 year) reduces ischemic events but increases the risk of major bleeding.
In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.).
Bonaca et al. (Sat,) studied this question.